Table 1.
Summary of demographics and baseline characteristics (safety population)
| ZyCoV-D (n=13 851) | Placebo (n=13 852) | Overall (N=27 703) | |
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 36·4 (13·83) | 36·6 (13·76) | 36·5 (13·79) |
| Median (range) | 35·0 (12·00–88·00) | 35·0 (12·00–87·00) | 35·0 (12·00–88·00) |
| Age group, years | |||
| 12 to 17 | 448 (3·23) | 487 (3·52) | 935 (3·38) |
| 18 to <60 | 12 364 (89·26) | 12 338 (89·07) | 24 702 (89·17) |
| ≥60 | 1039 (7·50) | 1027 (7·41) | 2066 (7·46) |
| Gender | |||
| Female | 4506 (32·53%) | 4605 (33·24%) | 9111 (32·89%) |
| Male | 9345 (67·47%) | 9247 (66·76%) | 18 592 (67·11%) |
| Participant test for detection of antibody performed | |||
| No | NA | 2 (0·01%) | 2 (0·01%) |
| Yes | 12 043 (86·95%) | 12 020 (86·77%) | 24 063 (86·86%) |
| Missing | 1808 (13·05%) | 1803 (13·21%) | 3638 (13·13%) |
| SARS-CoV-2 antibody | |||
| Absent | 10 136 (73·18%) | 10 145 (73·24%) | 20 281 (73·21%) |
| Present | 1862 (13·44%) | 1846 (13·33%) | 3708 (13·38%) |
| Missing | 45 (0·32%) | 29 (0·21%) | 74 (0·27%) |
| Participant at risk (comorbidities) | |||
| No | 13 142 (94·88%) | 13 112 (94·66) | 26 254 (94·77) |
| Yes | 709 (5·12%) | 740 (5·34) | 1449 (5·23) |
| Stable chronic heart disease | 167 (1·21%) | 155 (1·12%) | 322 (1·16%) |
| Stable chronic lung disease | 13 (0·09%) | 7 (0·05%) | 20 (0·07%) |
| Controlled diabetic | 275 (1·99%) | 289 (2·09%) | 564 (2·04%) |
| Stable liver disease | 2 (0·01%) | 3 (0·02%) | 5 (0·02%) |
| Severe obesity | 18 (0·13%) | 14 (0·10%) | 32 (0·12%) |
| Other stable comorbidity | 295 (2·13%) | 293 (2·12%) | 588 (2·12%) |
Data are mean (SD), median (range), or n (%). NA=not applicable.